Tag: litigation

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Roblox Corporation (NYSE: RBLX) between October 30, 2025 and April 30, 2026, inclusive (the “Class Period”), of the important August 7, 2026 lead plaintiff deadline.

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds AeroVironment, Inc. (“AeroVironment” or the “Company”) (NASDAQ:AVAV) investors of the July 27, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.

Generated Record Operating Cash Flow of $54.1 Million; Maintained Profitability 

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Blaize Holdings, Inc. (NASDAQ: BZAI) resulting from allegations that Blaize may have issued materially misleading business information to the investing public.

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.

Latest Supply & Trading Agreement Represents Significant Progress Toward Company's Long-Term Objective of $1 Billion in Annualized Commercial Activity